Market Overview

Bernstein Says Onyx Acquisition Could Boost Amgen Earnings 25% by 2020

Share:
Related ONXX
How to Prepare for the New Year
UPDATE: Stifel Terminates Coverage on Onyx Pharmaceuticals Following Acquisition by Amgen
Related AMGN
Bank Of America Believes Shares Of Amgen Are Fairly Valued
CVS Says New Cholesterol Drug Types Could Be Costly
Today's Market: Biotech Correction, Social Media News And Geopolitical Events Moving Stocks (Seeking Alpha)

Shares of Amgen (NASDAQ: AMGN) rose nearly 7 percent Wednesday while Onyx Pharma (NASDAQ: ONXX) shares fell about percent following a mid-day Reuters report Amgen is now expected to pay $130/share in its acquisition of Onyx Pharmaceuticals (NASDAQ: ONXX).

RBC analyst Michael Yee is commenting on the rumor Thursday morning, suggesting more near-term gains could come if the acquisition goes through. Yee sees 0-6 percent added to Amgen EPS in 2014 on profit potential, price-to-earnings expansion, and interest from "growth investors." Further EPS gains of 5-8 percent could eventually be realized through overlapping expense cuts.

While investors in Amgen are taking profits Thursday morning, shares of Onyx are trading about $0.05 higher.

Latest Ratings for ONXX

DateFirmActionFromTo
Nov 2013Stifel NicolausTerminates
Aug 2013Maxim GroupDowngradesBuyHold
Aug 2013BMO CapitalMaintainsMarket Perform

View More Analyst Ratings for ONXX
View the Latest Analyst Ratings

Posted-In: Analyst Color News Rumors M&A Analyst Ratings

 

Related Articles (AMGN + ONXX)

Around the Web, We're Loving...